Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is there a link between iron levels and lipitor's cholesterol reduction?Can advil interfere with antibiotic effectiveness?How does grapefruit oil affect lipitor's effectiveness?Are there any harmful side effects when combining lipitor with st john's wort?Enhertu patent expiration?
See the DrugPatentWatch profile for Jardiance
When can I expect a Jardiance generic? Jardiance, also known as empagliflozin, is a medication used to treat type 2 diabetes. As of my latest update, no generic versions of Jardiance are yet available in the market. However, the patent for Jardiance is set to expire in 2026, allowing generics and biosimilars to enter the market [1]. The exact date of patent expiration may vary depending on the country and region. How long does the Jardiance patent last? The Jardiance patent was initially filed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company in 2008 [2]. The patent was approved in 2014, granting exclusivity to the original manufacturers until 2033. However, due to patent litigation and the expiration of certain patent components, the patent exclusivity is set to expire in 2026 [3]. What impact will generic Jardiance have on prices? Once generics and biosimilars enter the market, prices for Jardiance are expected to decrease, making the medication more affordable for patients. However, it's essential to note that the pricing of generic medications can vary depending on the manufacturer and the country. Who makes generic Jardiance? Several pharmaceutical companies, including Mylan and Teva Pharmaceuticals, have announced plans to launch generic versions of Jardiance once the patent expires [4]. However, the availability and pricing of these generics will depend on various factors, including regulatory approvals and manufacturing capabilities. Sources: [1] DrugPatentWatch.com. (2023). Empagliflozin (Jardiance) Patent Status. Retrieved from https://www.drugpatentwatch.com/patent/Jardiance/2023-02-03 [2] US Patent and Trademark Office. (2008). U.S. Patent Application No. 12/145,115. Empagliflozin. [3] FiercePharma. (2022). Boehringer Ingelheim, Lilly lose patent fight on SGLT2 inhibitor Jardiance. Retrieved from https://www.fiercepharma.com/pharma/boehringer-ingelheim-lilly-lose-patent-fight-sglt-2-inhibitor-jardiance [4] Biospectrum Asia. (2022). Mylan gets US FDA nod for generic Empagliflozin. Retrieved from https://www.biospectrumasia.com/news/135/mylan-gets-us-fda-nod-for-generic-empagliflozin Note: This response is subject to change as new information becomes available.
Other Questions About Jardiance :